Margaret Horn reports sale of 75,000 shares

Margaret A. Horn filed a Form 144 reporting sales of Common Stock.

Rhea-AI Filing Summary

Margaret A. Horn filed a Form 144 reporting sales of Common Stock. The filing lists a sale of $372,333.45 for 4,847 shares on 12/16/2025 and a sale of $7,542,022.50 for 75,000 shares on 01/07/2026. The excerpt also lists restricted stock unit grants dated 03/01/2022 (1,234 units), 03/01/2023 (1,273 units), 03/01/2024 (1,305 units) and 03/01/2025 (910 units).

Insights

Compliance & Insider Transactions Analyst

Form 144 notifies the SEC of proposed sales by an affiliate; two recent dispositions are shown.

The filing records two transactions: $372,333.45 for 4,847 shares on 12/16/2025 and $7,542,022.50 for 75,000 shares on 01/07/2026. These entries are presented as sales of Common Stock by Margaret A. Horn.

Restricted stock unit grants are listed with grant dates and unit counts (03/01/2022 through 03/01/2025). The filing traces recent dispositions; cash‑flow treatment and any broker/dealer methods are not stated in the provided excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Margaret A. Horn report in the Form 144 for RVMD?

She reported sales of Common Stock: 4,847 shares for $372,333.45 and 75,000 shares for $7,542,022.50. The filing lists these transactions with trade dates 12/16/2025 and 01/07/2026.

Does the Form 144 show any restricted stock units for the reporting person?

Yes. The filing lists RSU grants on 03/01/2022 (1,234), 03/01/2023 (1,273), 03/01/2024 (1,305) and 03/01/2025 (910). These appear as grant dates and unit counts in the excerpt.

Are the sale proceeds and share counts shown on Form 144 for RVMD?

Yes. The excerpt shows proceeds and share counts: $372,333.45 for 4,847 shares and $7,542,022.50 for 75,000 shares. Each amount is paired with its respective trade date in the filing.

Does the filing state who received the proceeds from these sales?

The excerpt does not state the recipient of sale proceeds. It lists the reporting person and transaction amounts, but cash‑flow treatment is not specified in the provided excerpt.

Which dates are associated with the reported transactions in the Form 144?

The sales are dated 12/16/2025 (4,847 shares) and 01/07/2026 (75,000 shares). RSU grant dates listed span 03/01/2022 to 03/01/2025 with unit counts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/13/2026 - 07:36 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001294192
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Revolution Medicines, Inc.
SEC File Number	001-39219
Address of Issuer	700 SAGINAW DR REDWOOD CITY CALIFORNIA 94063
Phone	650-481-6801
Name of Person for Whose Account the Securities are To Be Sold	Horn Margaret A
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	4722	470263.98	198173397	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2022	Restricted stock unit grant	Issuer			1234	03/01/2022	Services rendered
Common Stock	03/01/2023	Restricted stock unit grant	Issuer			1273	03/01/2023	Services rendered
Common Stock	03/01/2024	Restricted stock unit grant	Issuer			1305	03/01/2024	Services rendered
Common Stock	03/01/2025	Restricted stock unit grant	Issuer			910	03/01/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Margaret A. Horn c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	12/16/2025	4847	372333.45
Margaret A. Horn c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	01/07/2026	75000	7542022.50

144: Remarks and Signature

Remarks
Date of Notice	03/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/31/2023
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jack Anders, as Attorney-in-fact for Margaret A. Horn
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)